Heart failure (HF) is a progressive condition where the heart is unable to pump enough blood to meet the body’s needs. Common causes of HF include ischaemic heart disease (IHD), hypertension, cardiomyopathy, diabetes and thyroid disorders. Patients with HF generally require lifelong treatment, but often ask if their medications may be stopped once their symptoms have improved. In this case study, Dato’ Dr Azmee Mohd Ghazi shares his clinical experience treating HF and the current evidence for HF therapy withdrawal.
RB Health is committed to support healthcare quality improvement through CME activities that help physicians stay updated with the latest developments in medicine. At the RB symposium held in Kuala Lumpur, two distinguished speakers gave their insights into the management of acid reflux and sore throat – two of the most common reasons for patients to visit their doctors.
In a dinner symposium organised by Boehringer Ingelheim Malaysia, Dr Alice Cheng spoke on how cardiovascular outcome trials (CVOTs) have evolved and impacted the use of antihyperglycaemic agents such as sodium-glucosecotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in clinical practice.
At the AstraZeneca sponsored-symposium, held in conjunction with Diabetes Asia 2019, a panel of distinguished speakers spoke about the importance of preventing cardiovascular (CV) and renal complications in patients with type 2 diabetes mellitus (T2DM), in addition to addressing glucose control. Chaired by Professor Dato’ Dr Mafauzy Mohamed, the panel discussed updated outcomes of landmark studies supporting the benefit of dapagliflozin (Forxiga®, AstraZeneca) in patients with T2DM.
In a lecture tour series organised by Boehringer Ingelheim Malaysia, Professor Michael Cummings spoke on the latest linagliptin analyses that shed new light on the long-term safety profile of the dipeptidyl peptidase-4 (DPP-4) inhibitor across a broad range of patients with type 2 diabetes (T2D).
The interest in healthcare and medicine is evident from companies in fields unrelated to healthcare venturing into the scene. With this interest is the boom of healthcare facilities, both clinics and hospitals, being set up in the country. As of end 2017, Malaysia counted 200 private hospitals with 14,799 beds. [https://www.export.gov/article?id=Malaysia-Healthcare, Accessed on 18 November]
The recent launch of Sunway Medical Centre Velocity (SMCV) coincides with the boom of hospitals established in the country. However, its founding should not be seen as jumping on the bandwagon. Rather, the hospital is a carefully planned and executed venture. MIMS spoke to SMCV’s Chief Executive Officer, Wilson Choo, to get his insights on the establishment of SMCV and his vision for SMCV in the short and long term.
Bumrungrad International Hospital was founded in 1980 and has since grown to become one of the most reputable hospitals in the region. The recipient of numerous international awards and accreditations, Bumrungrad International is one of the largest private hospitals in Southeast Asia, catering to over 1.1 million patients from over 190 countries annually.
In an exclusive interview with MIMS, Kenny Lim, Chief Information Technology Officer of Bumrungrad International Hospital shared his views on how the hospital has continued to improve its services to patients with particular emphasis on the use of clinical decisions support tools.
In collaboration with the Malaysian Society of Infectious Diseases and Chemotherapy,Sanofi Pasteur Malaysia commemorated the launch of VaxigripTetra® by inviting three distinguished speakers to provide valuable insights into the prevalence of influenza and how vaccination can truly impact the health status of patients in general.
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.